论文部分内容阅读
目的观察重组人脑利钠肽(rh BNP)治疗慢性阻塞性肺疾病(COPD)合并急性左心衰竭患者的治疗效果。方法将COPD合并急性左心衰竭患者50例随机分为研究组和对照组各25例。比较2组临床疗效、心率、血压、尿量、心功能、血气分析指标的变化情况,以及常规抗心力衰竭药物的使用剂量和不良反应发生率。结果研究组总有效率为92.0%高于对照组的68.0%,差异有统计学意义(P<0.05);治疗前2组患者心率、血压、尿量、心功能、血气分析指标比较差异均无统计学意义(P>0.05),治疗后2组患者心率、血压均无显著差异(P>0.05),但研究组尿量显著高于对照组(P<0.05);治疗后2组脑利钠肽(BNP)、左室射血分数(LVEF)、左室舒张末容积(LVDD)、动脉血气分析等指标比较差异均有统计学意义(P<0.05)。研究组常规心力衰竭药物的使用剂量及不良反应的发生率均低于对照组,差异均有统计学意义(P<0.05)。结论 rh BNP治疗COPD合并急性左心衰竭患者疗效显著,不仅能有效缓解患者的临床症状,改善心功能,且能减少常规心力衰竭药物的使用剂量,降低不良反应的发生,值得临床推广应用。
Objective To observe the therapeutic effect of recombinant human brain natriuretic peptide (rh BNP) on patients with chronic obstructive pulmonary disease (COPD) complicated with acute left heart failure. Methods Fifty patients with COPD complicated with acute left heart failure were randomly divided into study group (25 cases) and control group (25 cases). The changes of clinical efficacy, heart rate, blood pressure, urine output, heart function and blood gas analysis indexes were compared between the two groups, as well as the dosage of the conventional anti-heart failure drugs and the incidence of adverse reactions. Results The total effective rate was 92.0% in the study group, which was significantly higher than that in the control group (68.0%, P <0.05). There was no significant difference in heart rate, blood pressure, urine volume, cardiac function and blood gas analysis between the two groups before treatment (P> 0.05). There was no significant difference in heart rate and blood pressure between the two groups after treatment (P> 0.05), but urine volume in the study group was significantly higher than that in the control group (P <0.05) The levels of BNP, LVEF, LVDD and arterial blood gas analysis were significantly different (P <0.05). The study group conventional heart failure drug dosage and adverse reactions were lower than the control group, the difference was statistically significant (P <0.05). Conclusion rh BNP is effective in treating COPD with acute left heart failure. It not only can effectively relieve the clinical symptoms and improve cardiac function, but also reduce the dose of conventional heart failure drugs and reduce the incidence of adverse reactions, which is worthy of clinical application.